In recognition of Pain Awareness Month (PAM), the Let’s Talk Pain Coalition today launched the Pain Medication Safety Series, an online video series featuring candid dialogues between health care professionals, people with pain and their caaregivers about the safe and appropriate use of pain therapies. A complete listing of episodes with descriptions is available at www.letstalkpain.com/painmedsafety.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/letstalkpain/45730/
The Department of Veterans Affairs (VA) is celebrating exceptional care for Veterans this week, May 2 – 6 as part of the nationally recognized Research Week. This year’s theme, “Discovery and Collaboration for Exceptional Health Care,” celebrates two crucial elements of VA research: dedicated follow-through on important research findings to optimize medical therapies for Veterans and others; and vital research and care collaborations between VA and academic institutions, other government agencies, and health-related industry.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/va/48428/
Phoenix Children’s Hospital announced the creation of the Ronald A. Matricaria Institute of Molecular Medicine today, with the goal to unlock genetic codes and develop drug therapies in real time to improve the outcome for thousands of young patients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59399-phoenix-children-s-hospital-visionary-institute-of-molecular-medicine
It may officially be Fall, but at ARIA Resort & Casino in Las Vegas the heat is still on. ARIA is one of the few Las Vegas Hotels with a year round pool and cabanas. Guests can enjoy water heated to a perfect 82 degrees whether it is 65 or 105 degrees outside. Cabanas with full food and beverage options as well as HD TVs, an iPod dock and even wifi are also available starting at $200 for up to 8 people.
Not in the mood to lounge by the pool? ARIA Resort & Casino offers one of the best spa experiences in Las Vegas as well. From traditional treatments to our innovative signature series therapies, there is literally something for everyone.
To view Multimedia News Release, go to http://www.multivu.com/players/English/57841-mgm-aria-resort-and-casino-las-vegas/
http://www.getthehormonecure.com Dr.
Sara Gottfried refuses to accept the traditional medical thinking that
feeling cranky, asexual, tapped out, and sleep-deprived is just part of
being female and aging, and that prescription medication will fix all
problems. In The Hormone Cure, she combines natural therapies with
rigorous scientific testing to help women feel fully alive, especially
in the years prior to menopause. Using an informative questionnaire to
identify common symptoms of hormonal imbalance such as insomnia, low
sex drive, lack of energy, moodiness, hot flashes, and more; detailing
causes; and offering solutions in non-judgmental and thoughtful
language, Dr. Gottfried provides a novel plan based on solid scientific
research. She believes you don't find a cure at the bottom of a pill
bottle.
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (“DelMar Pharma” or “DelMar”) discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing new therapies for patients with little to no treatment options.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7037951-delmar-pharmaceuticals-glioblastoma-brain-tumor-awareness-month
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.
The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350554-phrma-report-innovation-rare-diseases/
During a live global event, Elekta announced the launch of Versa HD™, an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers. Featuring high precision beam shaping and tumor targeting, Versa HD also unveils new capabilities designed to maximize health care system resources and deliver highly sophisticated therapies without compromising treatment times.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60246-elekta-sets-new-benchmark-for-cancer-treatment-launch-of-versa-hd-system
Nearly 12 million men in the U.S. suffer from symptoms related to benign prostatic hyperplasia (BPH), an enlargement of the prostate that can cause issues such as frequent and weak urinary streams and sleep deprivation from getting up repeatedly during the night to urinate. Since traditional BPH therapies such as daily medications and more invasive or surgical procedures often result in unwanted side effects and complications, more than 54 percent of men who would benefit from treating their BPH choose not to do anything1. With today’s national introduction of the FDA-cleared Rezūm® System, NxThera provides urologists and their patients suffering from symptomatic BPH with a new, safe and effective minimally-invasive, office-based treatment option which improves quality of life and preserves sexual function2 – one of the main reasons many men choose to forego medications or more invasive procedures.
“Men suffering from BPH are constantly evaluating the trade-offs between maintaining their current declined quality of life or treating their BPH symptoms and possibly incurring long term side effects,” said Dr. Kia Michel, M.D., a urologist at Comprehensive Urology in Los Angeles who recently performed the procedure as part of a nationally televised segment on prostate health. “Of all the minimally-invasive BPH treatments I’ve performed, Rezūm is the most effective and most versatile treatment available to patients – and the results have been excellent.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7933151-nxthera-rezum-therapy/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area, announced today that the EU Committee for Medicinal Pro-ducts for Human Use (CHMP) recommended that the European Commission approve the use of Xadago™ (safinamide) as add-on to L-dopa alone or in combination with dopamine agonists, entacapone, amantadine, and/or anticholinergics, for the treatment of patients with mid-late stage Parkinson’s disease experiencing motor fluctuations despite being stabilized on ‘Standard of Care’.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7406951-chmp-xadago-parkinsons/
